Patients Use Fewer Opioids Following Enrollment In Medical Cannabis Program

The study's findings are similar to those reported among enrollees in other states' medical cannabis programs, including the experiences of patients in Illinois, Michigan, Minnesota, New Mexico, and elsewhere.

NEW YORK:  Patients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician. Investigators from GPI Clinical Research labs in Rochester and the University of Buffalo assessed trends in patients’ medical cannabis and prescription drug use following Read the full article…

Study: Cannabis Use Associated With Lower Risk Of Atrial Fibrillation Among Patients Hospitalized For Heart Failure

Cannabis Use Associated With Lower Risk Of Atrial Fibrillation Among Patients Hospitalized For Heart Failure

NEW YORK: Cannabis exposure is associated with lower instances of atrial fibrillation (arrhythmia) in patients hospitalized for heart failure, according to data published in the American Journal of Cardiology. A team of investigators from Seton Hall University, the University of Alabama at Birmingham, and elsewhere assessed the relationship between cannabis exposure and atrial fibrillation in a cohort of nearly four million Read the full article…

Alternative Health CEO Updates Shareholders On Spinoff Plans

Management has received Board approval to explore a spinoff plan for the Company’s non-cannabis assets,

TEXAS: The CEO of Alternate Health CEO this week provided further details about the company’s spinoff plans and key milestones for the upcoming quarters. “The Company has been very active this year adjusting our business for revenue generation and growth, including developing our potential spinoff plan for Alternate Health’s non-cannabis assets,” says Dr. Michael Murphy, Chairman and Read the full article…

Court Rejects Challenge To DEA’s Classification Of Marijuana Extracts

Court Rejects Challenge To DEA's Classification Of Marijuana Extracts

CALIFORNIA: A three judge panel for the Ninth Circuit Court of Appeals has denied a petition filed by the Hemp Industries Association challenging the DEA’s authority to establish a new administrative drug code specifically for marijuana extracts. The DEA first announced the proposed rule change in 2011, but did not enact the new policy until January 13, 2017. In a Read the full article…

Oregon’s Medical Marijuana Growers Prepare for Tracking

OLCC news

OHA & OLCC Holding Information Sessions across the State OREGON:  This summer approximately 2,000 medical marijuana growers will need to start using Oregon’s Cannabis Tracking System (CTS) to ensure the marijuana they grow for patients is tracked and reported.  This week the Oregon Health Authority (OHA) and the Oregon Liquor Control Commission (OLCC) launched a series Read the full article…

Tilray Shares Preliminary Data From The Largest National Longitudinal Medical Cannabis Patient Study in Canada

Study finds significant reduction in opioid use and improvements in quality of life within first 6 months.

CANADA: Tilray Canada Ltd., a medical cannabis leader committed to advancing scientific knowledge of cannabinoids, shared preliminary data today from the Tilray Observational Patient Study (TOPS), a Tilray-sponsored survey of medical cannabis patients using Tilray products currently underway at 18 different medical clinics in five provinces in Canada. As Canada’s largest national medical cannabis longitudinal study, Read the full article…

Tikun Olam and Ilera Healthcare Announce Pennsylvania Partnership

Tikun Olam and Ilera Healthcare Announce Pennsylvania Partnership
to Deliver Science-Backed Cannabis Products to PA MMJ Patients

PENNSYLVANIA and NEW YORK:  Tikun Olam, the world leader in cannabis science, and Ilera Healthcare, Pennsylvania’s premier medical marijuana cultivator, processor and dispenser, have finalized a deal to bring Tikun’s world-renowned medical marijuana strains to medical cannabis patients in the Keystone State later this year. This partnership combines Tikun Olam’s history of peer-reviewed scientific research and Read the full article…

Study: Cannabis Exposure Not Associated With Residual Adverse Impact On Cognition

"Associations between cannabis use and cognitive functioning in cross-sectional studies of adolescents and young adults are small and may be of questionable clinical importance for most individuals."

PENNSYLVANIA:  Cannabis exposure in adolescents and young adults is not associated with any significant long-term detrimental effects on cognitive performance, according to a systematic literature review  published Wednesday in the journal JAMA Psychiatry. Investigators affiliated with the University of Pennsylvania, Perelman School of Medicine and with the Children’s Hospital of Pennsylvania reviewed data from 69 separate studies published between Read the full article…

Curaleaf Opens Medical Cannabis Dispensary In Oxford To Service Central Massachusetts

Curaleaf medical marijuana dispensary

MASSACHUSETTS: Curaleaf, a provider of high-quality, reliable, and safe cannabinoid-based products, officially opened its second medical cannabis dispensary in Massachusetts. Now patients in central Massachusetts can more easily access needed medical care. This new location in Oxford joins the company’s successful Hanover dispensary that opened in fall of 2017. Located at 425 Main Street, Curaleaf offers a Read the full article…

Study: Cannabinoid Therapy Improves Dystonia In HD Patients

"Treatment with cannabinoids in all cases lead to an improvement of motor symptoms, mainly driven by improvement of dystonia," authors concluded. Patients generally reported "no relevant side effects."

GERMANY: Cannabinoid treatment is associated with improvements in dystonia in patients with early-onset Huntington’s disease, according to observational data published online ahead of print in the Journal of Huntington’s Disease. A team of investigators from Germany and Austria assessed the treatment of various synthetic or organic cannabinoid preparations – including Sativex, dronabinol, and nabilone - in seven HD patients who had been Read the full article…